Related Experiment Video

Updated: Jun 24, 2026

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Pathology: are circulating tumor cells predictive of overall survival?

Klaus Pantel1, Sabine Riethdorf

  • 1Institute of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. pantel@uke.uni-hamburg.de

Nature Reviews. Clinical Oncology
|April 1, 2009
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Related Experiment Videos

Last Updated: Jun 24, 2026

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Articles linked to this work by shared authors, journal, and citation graph.

Circulating Tumor Cells: From Basic to Translational Research.

Clinical chemistry·2024

EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma.

Scientific reports·2023

Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy.

Clinical and translational science·2023

RNF40 epigenetically modulates glycolysis to support the aggressiveness of basal-like breast cancer.

Cell death & disease·2023

[Liquid Biopsy - A new diagnostic concept in oncology].

Laryngo- rhino- otologie·2023

Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients.

International journal of molecular sciences·2023

Exploring the landscape of targetable alterations in patients with glioblastoma.

Nature reviews. Clinical oncology·2026

AI-based augmentation of oncology clinical trials.

Nature reviews. Clinical oncology·2026

Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management.

Nature reviews. Clinical oncology·2026

De-escalation trials in multiple myeloma: past, present and future.

Nature reviews. Clinical oncology·2026

Towards liquid biopsy-based analysis of antitumour immunity.

Nature reviews. Clinical oncology·2026

CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.

Nature reviews. Clinical oncology·2026

The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?

Future oncology (London, England)·2026

Afirma Xpression Atlas Alteration Status Is Associated with Malignancy Risk in Indeterminate Thyroid Nodules.

Thyroid : official journal of the American Thyroid Association·2026

Association of Imaging-Defined Deep Invasion and Tumor Volume With Clinical Cervical Lymph Node Metastasis in Hypopharyngeal Carcinoma.

Journal of computer assisted tomography·2026

InflaMix Predicts Severe CRS, ICU Admission, and Progression-Free Survival After CAR-T Therapy in LBCL.

European journal of haematology·2026

Nuclear Pan-Lysine Lactylation Immunoreactivity Is Associated With Poor Prognosis in Intrahepatic Cholangiocarcinoma.

Hepatology research : the official journal of the Japan Society of Hepatology·2026

Clinical impact of nociplastic symptom burden in individuals with fibromyalgia syndrome.

Pain management·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us